Actively Recruiting
Phase 12 Study of Investigational Agents With or Without Pembrolizumab and Chemotherapy in Advanced Esophageal Squamous Cell Carcinoma Previously Treated With PD-1PD-L1 Therapy
Led by Merck Sharp & Dohme LLC · Updated on 2026-10-07
230
Participants Needed
58
Research Sites
95 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a Phase 12, multicenter, randomized, open-label study to evaluate the safety and effectiveness of various investigational agents, with or without pembrolizumab andor chemotherapy, for treating participants with advanced esophageal squamous cell carcinoma ESCC who have previously received PD-1PD-L1 based treatment. The study aims to address treatment options for participants who have progressed after prior standard therapies. Participants are assigned to different treatment groups, including chemotherapy agents paclitaxel or irinotecan given intravenously on specific schedules, pembrolizumab combined with MK-4830 plus paclitaxel or irinotecan, pembrolizumab with MK-4830 plus lenvatinib taken orally daily, or sacituzumab tirumotecan at two dose levels administered intravenously on days 1, 15, and 29 of each 42-day cycle. Some treatment arms are no longer enrolling. Supportive care medications such as antihistamines, steroids, and others may be used to manage side effects. Participants undergo assessments during a safety lead-in phase lasting about 3 weeks and an efficacy phase lasting up to approximately 48 months or longer. Researchers monitor for dose-limiting toxicities, adverse events, treatment discontinuation due to side effects, and objective response rates. Longer-term outcomes include progression-free survival, duration of response, and overall survival, with safety monitoring continuing up to around 70 months. The study involves regular treatment cycles and follow-up visits over several years.
CONDITIONS
Brief Title
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
Research Team
T
Toll Free Number
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here